Methods of screening for antagonists of APM1/GZIP
AssigneeSerono Genetics Institute S.A.
InventorsIlya Chumakov, Oxana Guerassimenko
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GZIP polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
Claims12
A method of screening for an antagonist that blocks the binding of an APM1 polypeptide or an APM1 polypeptide fragment to a GZIP polypeptide comprising:
- a) contacting the APM1 polypeptide comprising SEQ ID NO:4, or an APM1 polypeptide fragment comprising amino acids 108-244 of SEQ ID NO:4 with a GZIP polypeptide comprising amino acids 21-298 of SEQ ID NO:2 in the presence and absence of a test compound;
- b) detecting binding of the GZIP polypeptide comprising amino acids 21-298 of SEQ ID NO:2 to the APM1 polypeptide according to SEQ ID NO:4, or an APM1 polypeptide fragment comprising amino acids 108-244 of SEQ ID NO:4 in the presence or absence of a test compound;
- and
- c) identifying a test compound as an antagonist of GZIP/APM1 interaction if the binding of APM1 to GZIP is blocked in the presence of said test compound.
Dependencies are inferred from the claim text.